CION Ameerpet
If a scan has found something and you are trying to work out how much time you have, here is the honest answer: ovarian cancer does not have one growth rate. Some tumours barely change over years. One type — the commonest — stays invisible for years and then moves quickly. The type matters far more than the calendar.
People searching how fast ovarian cancer grows are usually looking for one number — a doubling time, a number of months, something to measure the wait against. That number does not exist, and any page that gives you one is guessing. Ovarian cancer is not one disease. It is a group of tumours that share an address and very little else, and their growth rates differ by an order of magnitude.
The most useful framework is the one pathologists use. Type I tumours — low-grade serous, mucinous, many endometrioid and clear cell cancers, and borderline tumours — grow slowly, often over years, and frequently stay confined to one ovary long enough to be caught there. Type II tumours are dominated by high-grade serous carcinoma, which accounts for roughly seven in ten epithelial ovarian cancers. This is the type that behaves quickly, and it is the reason ovarian cancer has the reputation it has.
There is a second reason no one can quote you a personal growth rate. Cancers are not watched while they grow. Once a tumour is found it is treated, so the ovarian cancer growth rate is worked out indirectly — from the tumour's grade under the microscope, from how many of its cells are dividing, from mutation patterns, and occasionally from two scans done months apart for an unrelated reason. Those methods describe groups of tumours well. They do not predict what any one tumour will do next month.
Indolent type I tumours can sit for years with little change. High-grade serous carcinoma is quiet while it is microscopic, then disseminates quickly once it is established.
A large slow tumour is often less dangerous than a small high-grade one. What the pathologist writes about grade and subtype predicts behaviour far better than centimetres do.
Rapidly dividing cells are exactly what platinum-based chemotherapy targets. High-grade serous ovarian cancer is unusually chemotherapy-sensitive, which is why advanced disease is still treated with intent.
High-grade serous ovarian cancer — the commonest and fastest-moving type — usually begins not in the ovary but at the fimbrial end of the fallopian tube, as a microscopic lesion called serous tubal intraepithelial carcinoma (STIC). By sequencing paired tube and ovarian tumours and modelling how the mutations accumulated, researchers estimated that around 6.5 years pass between that first tubal lesion and a recognisable ovarian cancer, and only about two more years before it has spread beyond the pelvis. The disease is slow for years while it is invisible, and fast once it is not. Source: Labidi-Galy SI et al., Nature Communications (2017); Kurman RJ & Shih IeM, American Journal of Surgical Pathology (2010).
Your pathology report names a subtype and a grade. Those two words tell a specialist more about speed than any scan does. Here is how each of the common types actually behaves.
This is the type most people mean when they ask about ovarian cancer. It arises mostly in the fallopian tube, carries a TP53 mutation in almost every case, and has a very high proportion of dividing cells. Once it becomes invasive it sheds cells into the peritoneal fluid, which carries them around the abdomen. That is why it is usually found at stage III or IV rather than stage I — not because it took a long time to be noticed, but because its route of spread does not need years.
The corollary matters just as much. Because its cells divide so quickly, high-grade serous carcinoma responds to platinum-based chemotherapy better than almost any other solid tumour, and complete remission after first-line treatment is common. Speed of growth and treatability are not opposites here. See how ovarian cancer spreads through the peritoneum for the mechanism.
A genuinely different disease that happens to share a name. Low-grade serous carcinoma has few dividing cells, often takes years to enlarge appreciably, and tends to occur in younger women. Women sometimes discover, looking back at old scans, that the abnormality was visible years earlier and was called something benign.
The trade-off is that slow-growing cells are poor targets for chemotherapy, which works on cells that are dividing. Low-grade serous cancers respond less well to chemotherapy than high-grade ones, and hormonal treatment and complete surgical removal carry more weight in the plan. Slower is not automatically better news; it changes which treatment works rather than how serious it is.
Both are frequently linked to endometriosis, and both tend to present as a distinct mass on one ovary rather than as sheets of disease across the abdomen. Because they produce a lump that shows up on ultrasound and causes local symptoms, a higher proportion are found at stage I or II than with high-grade serous cancer.
Endometrioid tumours are often low grade and behave indolently. Clear cell carcinoma is the exception in this pair: it can be found early yet behaves less predictably, is more resistant to platinum-based chemotherapy, and is more prone to recur. Again, the speed of growth and the response to treatment are separate questions.
Mucinous ovarian tumours are among the largest tumours found in the human body, and they can reach a remarkable size while remaining confined to a single ovary. They grow steadily rather than explosively, and abdominal swelling from sheer bulk is often the presenting complaint.
Two cautions come with them. A mucinous tumour in the ovary is sometimes a deposit from a primary cancer of the appendix, bowel or stomach, so the work-up looks beyond the pelvis. And when true mucinous ovarian cancer does spread, it responds less reliably to standard platinum-based chemotherapy than high-grade serous disease does.
Borderline tumours grow, sometimes to a considerable size, but they do not invade the underlying tissue in the way a carcinoma does. They occur mostly in younger women, they are usually confined at diagnosis, and outcomes after removal are excellent. A borderline result on a pathology report is genuinely different news from a carcinoma.
They still need proper follow-up. A minority recur, occasionally years later, and a small number of serous borderline tumours are the starting point for low-grade serous carcinoma. That is an argument for staying in follow-up, not for treating a borderline tumour as though it were an aggressive cancer.
These arise in teenagers and young women, and they are the genuinely fast-growing ovarian tumours. A germ cell tumour can enlarge noticeably within weeks, and it often announces itself with sudden pain, a palpable mass or torsion rather than with the slow symptom drift of epithelial cancer. Blood markers frequently rise in step with it.
Their speed is also their weakness. Germ cell tumours are highly sensitive to chemotherapy, and even advanced disease is usually curable, often while preserving fertility. Rapid growth in a young woman is a reason to be seen quickly, not a reason to assume the worst outcome.
Granulosa cell tumours and their relatives are typically indolent. Many are hormone-producing, so they announce themselves early through irregular bleeding, post-menopausal bleeding or, in younger girls, early puberty. Most are confined to one ovary when they are found.
Their unusual feature is the timing of recurrence. A granulosa cell tumour can return five, ten or even twenty years after apparently successful treatment, which is why follow-up runs for far longer than with epithelial cancers. Slow growth stretches the whole timeline, including the part after treatment.
If high-grade serous cancer spends years as a microscopic tubal lesion, the obvious question is why it is not caught in that window. There are three reasons, and none of them is the patient's fault.
The first is anatomy. The ovaries and tubes sit deep in the pelvis inside a cavity that has room to spare, and the peritoneum is a large, mobile surface. A tumour can seed that surface without pressing on anything that hurts. This is also why how quickly ovarian cancer spreads is a slightly misleading question: it does not need to invade its way outward inch by inch, because loose cells travel in the peritoneal fluid and settle wherever it flows.
The second is that the early symptoms are ordinary. Bloating, feeling full quickly, pelvic discomfort and needing to pass urine more often are all common complaints with common benign explanations. The pattern that matters is a new one — present on most days, over weeks rather than years — and even then, most women with that pattern do not have cancer.
The third is the one that gets soft-pedalled elsewhere, so let us be direct: there is no effective screening test for ovarian cancer, for anyone. A randomised trial of more than 200,000 women followed for a median of sixteen years found that annual CA-125 screening with ultrasound did not reduce deaths from ovarian cancer. That holds for women at average risk and for women carrying a BRCA variant. CA-125 and pelvic ultrasound are useful for investigating a symptom or a known mass. They are not a safety net, and no one should be reassured by a normal result they did not need.
The peritoneal cavity accommodates a growing tumour without producing early pain. Space, not slowness, is what buys the disease its silence.
Cells shed into peritoneal fluid and settle on distant surfaces. That is why stage can jump without any dramatic change in tumour size.
Annual CA-125 and ultrasound screening did not lower ovarian cancer deaths in a large randomised trial. Symptom-led assessment remains the realistic route to earlier diagnosis.
For women with a confirmed BRCA variant, surveillance is not protective — risk-reducing surgery is what changes the odds, and it is a decision made with genetic counselling.
Source for the screening finding: the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), Menon U et al., The Lancet (2021).
None of these confirms cancer, and none of them can be read on its own. Each is a reason to be assessed within days rather than to wait for the next routine appointment.
Abdominal swelling that visibly progresses over a few weeks usually means fluid accumulating, not fat or gas. That warrants prompt imaging rather than dietary advice.
Shortness of breath with abdominal swelling can mean fluid pressing on the diaphragm or collecting around a lung. It needs same-week assessment.
An ovarian lesion that has grown or become more solid, more vascular or more complex since a previous scan is behaving in a way that needs specialist review.
Persistent vomiting, colicky pain and no bowel movement can indicate disease affecting the bowel. This is an emergency assessment, not a clinic appointment.
Losing weight quickly while the abdomen is getting bigger is a specific and important combination. It should not be attributed to appetite or stress without imaging.
Ordinary gut and hormonal symptoms wax and wane. Symptoms that get steadily worse each week, without better days, are describing a different process.
If any of these apply, ask for an assessment now rather than waiting for a scheduled review. In most cases the explanation turns out to be benign — and where it is not, the interval between noticing and starting treatment is one of the few parts of this that is genuinely within reach.
A 45-minute consultation with a specialist who will tell you what your imaging and pathology actually show, what type of tumour behaves how, and how urgently anything needs to happen. No cost for the first visit.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
First consultation free, and no referral needed. If your findings suggest a slow-growing or benign tumour, we will say so plainly rather than rushing you into treatment.
Almost everyone asking about growth rate is really asking whether the wait they are facing is safe. Here is what a properly run pathway looks like, and where genuine urgency sits.
Bloating, early satiety, pelvic pain or urinary change that is new and present on most days for two to three weeks deserves an examination and usually an ultrasound. Two weeks is a sensible ceiling, not a deadline you have already missed if you have waited longer.
A pelvic ultrasound plus CA-125, with HE4 and the ROMA score where the situation calls for it, usually settles the question. Most scans find a benign explanation. Where they raise a real concern, everything after this step should move faster.
A contrast CT of the chest, abdomen and pelvis maps how far disease has already travelled. This is the study that decides the sequence of treatment, so it should not be left sitting in a queue once suspicion is real.
Every case that raises a question at CION is discussed by a multidisciplinary group — medical oncology, radiology and pathology together — rather than decided by one clinician. This is a discussion measured in days and it is where the sequence of treatment is set.
Either surgery first with chemotherapy after, or chemotherapy first to shrink disease before surgery. That decision rests on the CT findings and on general fitness. Both are standard, evidence-based routes; one is not a downgrade of the other. The options are set out on our ovarian cancer treatment page.
Cytoreductive surgery for ovarian cancer is coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there; chemotherapy and maintenance therapy are delivered in-house at CION. A short, planned wait for the right surgeon at the right centre is safer than an immediate operation by a team that does not do this work regularly. Chemotherapy, where it comes first, can usually start within a couple of weeks of the diagnosis being confirmed.
Days and weeks matter here; single days rarely do. If you are being asked to wait months for a scan or a decision, that is the point to seek a second opinion — not because your tumour will transform overnight, but because momentum is the part of this pathway that most affects outcome.
Questions about growth rate almost always come with a report in hand and no one available to explain it. A subtype, a grade, a proliferation index, a line about peritoneal deposits — these are the words that decide how quickly your disease is likely to behave, and reading them out loud with someone who does this daily changes the whole picture. That is a conversation, not a test.
Your first consultation at CION is free and runs to about 45 minutes. We go through your imaging and pathology, explain what your specific subtype and grade actually predict, and set out what needs to happen this week, this month, and what does not need to happen at all. Every case that raises a question goes to a tumour board rather than to a single opinion.
On capability, we would rather be plain than impressive. CION delivers medical oncology in-house: platinum-based chemotherapy and maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, along with genetic counselling and BRCA and HRD testing, nutrition support and long-term follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC and PET-CT are coordinated with specialist partner centres and may be billed there. If you would rather start with the broader picture, the complete ovarian cancer guide covers types, stages and treatment in one place, and you can also read how common ovarian cancer is in India.
Free, and long enough to go through a pathology report line by line rather than summarising it in a sentence.
Medical oncology, radiology and pathology review the same films and slides together, which is how sequencing decisions should be made.
Delivered at CION across 35+ centres, so treatment and follow-up happen near where you live rather than requiring repeat trips to one city hospital.
Debulking surgery is performed by specialist gynaecologic-oncology surgeons at partner centres and may be billed there. You should know that before you start, not after.
Not as directly as it sounds. Growth rate is one input into prognosis; stage at diagnosis, whether all visible disease can be removed at surgery, tumour subtype, BRCA and HRD status, and general fitness all weigh at least as heavily. High-grade serous cancer grows fast and responds well. Low-grade and clear cell cancers grow slowly and respond less well. The two variables pull in different directions often enough that neither predicts the other.
You will find stage-specific and subtype-specific survival percentages on the internet, and they are worth treating with caution. Most are drawn from cohorts diagnosed a decade or more ago, before PARP-inhibitor-class maintenance therapy and routine BRCA and HRD testing changed first-line treatment. They average across substages and subtypes that behave very differently, and they mix patients who had complete surgical removal with those who did not. A number built that way can be badly wrong in either direction for one person.
What CION can honestly publish is its own outcome alongside the national one, so the comparison is visible rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is one-year survival across a whole treated population — not a cure rate, and not a forecast for any individual. Your own outlook is a conversation with your oncologist once your stage, subtype and molecular results are known.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Published stage-specific figures are historical, averaged across dissimilar subtypes, and mix complete with incomplete surgery. They describe an old group, not your treatment.
*One-year survival rates. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
There is no single answer, because ovarian cancer is several different diseases. Borderline tumours, low-grade serous, mucinous and many endometrioid cancers grow slowly, often over years, and frequently stay confined to one ovary. High-grade serous carcinoma, which makes up roughly seven in ten epithelial ovarian cancers, behaves differently: it stays microscopic for a long period and then spreads quickly across the peritoneal cavity once it becomes invasive. Germ cell tumours in young women are the fastest of all and can enlarge noticeably within weeks. Your pathology report is what answers this question for you, because the subtype and grade written on it predict behaviour far better than the size of the tumour does.
Nobody can give you a reliable interval, because a cancer that is found is treated rather than watched. What is known is that high-grade serous cancer does not need to grow through tissue to change stage. It sheds cells into the peritoneal fluid, which carries them across the abdomen, so disease can appear at distant surfaces without the original tumour becoming much bigger. That is why stage can advance faster than size suggests. Slower-growing types behave more predictably and tend to stay local for longer. Genetic modelling of high-grade serous cancer suggests roughly two years between an established ovarian tumour and spread beyond the pelvis, but that describes a group average, not a countdown for any individual.
Yes, and this is well recognised. A woman can have a normal pelvic ultrasound and be diagnosed with advanced ovarian cancer within a year. It happens because high-grade serous cancer often starts as a microscopic lesion in the fallopian tube, which no ultrasound can see, and because peritoneal deposits are small and scattered before they become visible. This is also the reason that repeated scans are not offered as screening, even for women at high risk: a normal scan does not mean the following months are safe. If new symptoms appear after a normal scan, they need assessing on their own merit rather than being dismissed because the scan was clear.
No, and this is one of the more common reasons for unnecessary alarm. Functional cysts can enlarge rapidly within a single menstrual cycle and then disappear without any treatment. A cyst that bleeds into itself can expand quickly and painfully and is benign. Endometriomas and dermoid cysts also grow, usually slowly. What raises concern is not growth alone but the character of the lesion on ultrasound: solid areas, thick internal septations, increased blood flow, free fluid in the abdomen, and growth in a woman past the menopause. Speed on its own is weak evidence. Speed with those features on the scan is what prompts specialist referral.
A planned wait of a few weeks for the right operation at the right centre is standard practice and is not the thing that decides your outcome. What matters far more is whether the surgery removes all visible disease, and that depends on having a specialist gynaecologic-oncology surgeon and the correct pre-operative imaging. An immediate operation by a team that does not do this work regularly is the worse option. Use the interval: complete the staging scans, get the pathology and molecular tests moving, and improve nutrition and fitness before surgery. If the wait stretches into months rather than weeks, or your symptoms are clearly escalating, that is a genuine reason to seek a second opinion.
Often, yes, and this surprises people. Chemotherapy works on cells that are actively dividing, so tumours with a high proportion of dividing cells are the ones it hits hardest. High-grade serous ovarian cancer is unusually chemotherapy-sensitive for exactly this reason, and complete remission after first-line platinum-based treatment is common even when disease was widespread at diagnosis. Slower-growing tumours such as low-grade serous and clear cell carcinoma are less responsive, which is why surgery and hormonal treatment carry more weight in those plans. Growth rate therefore changes which treatment is likely to work, rather than simply making the outlook better or worse.
The first consultation is free and runs to about 45 minutes, with no referral needed. CION delivers medical oncology for ovarian cancer in-house: platinum-based chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and long-term follow-up. Debulking and other gynaecologic-oncology surgery, HIPEC and PET-CT are coordinated with specialist partner centres and may be billed there — we say that upfront rather than leaving you to discover it later. Every case that raises a question is reviewed at a tumour board, and cost estimates are given in writing before treatment starts.